Minnesota has established itself as a prominent hub for biotechnology, housing over 200 biotech companies that collectively employ more than 4,000 individuals. The state's biotech sector has seen significant investment, with at least $51.8 million raised by 10 companies in the first half of 2025 alone. This growth is underpinned by strong institutional support from renowned research entities and a vibrant ecosystem that fosters innovation and entrepreneurship.
Based in Minneapolis, Cell Culture Company (C3) offers comprehensive tools and services across various industries, including therapeutics, cell therapy, diagnostics, and genomics. Their state-of-the-art facilities, including regulated clean rooms and manufacturing operations, support robust growth and innovation.
Headquartered in Minneapolis, Bio-Techne is a leading provider of life science research tools, specializing in biotechnology and clinical diagnostics. Established in 1981, the company employs between 1,001 and 5,000 professionals and continues to play a pivotal role in advancing biotech research and applications.
Located in Maple Grove, Francis Medical focuses on minimally invasive treatment solutions for prostate, kidney, and bladder cancer. Founded in 2018, the company is currently conducting clinical trials for prostate tissue ablation, positioning itself as a frontrunner in cancer treatment innovations.
Invive specializes in epigenetics-based health risk assessments, providing personalized insights into individual health profiles. Their cutting-edge approaches in epigenetics are paving the way for more precise and effective health interventions.
Based in Minneapolis, Celcuity develops advanced diagnostic tests for cancer and autoimmune diseases. Their innovative diagnostics enhance patient care by providing more accurate and timely assessments, thereby improving treatment outcomes.
Located in St. Paul, Cerebral Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for refractory neurological diseases. Their focus on theranostics combines therapeutic and diagnostic capabilities to advance neurological treatment options.
Geneticure is at the forefront of personalized high blood pressure treatment, developing precision medicine approaches that tailor therapies to individual genetic profiles. Their work represents a significant advancement in personalized healthcare.
Geneos Therapeutics is dedicated to developing personalized cancer immunotherapies. By leveraging the latest in immunological research, the company aims to create more effective and individualized cancer treatment options.
Minnesota's biotech companies are making significant strides in personalized medicine, focusing on gene therapies, personalized treatment plans, and novel drug delivery systems. Companies like Geneticure and Geneos Therapeutics are pioneering efforts to tailor treatments to individual genetic profiles, enhancing efficacy and reducing side effects.
The robust healthcare infrastructure in Minnesota supports innovations in diagnostics and digital health. Companies such as Celcuity are developing advanced diagnostic tools that improve patient care, while others are leveraging AI and data analytics to enhance health data interpretation and disease detection.
Immunotherapy and regenerative medicine are key growth areas, with companies like Geneos Therapeutics and Cerebral Therapeutics developing next-generation immunotherapies and cell-based treatments. These advancements hold the promise of more effective treatments for various diseases, including cancer and neurological disorders.
Agricultural biotech is another significant area of innovation, with companies like Cibus utilizing non-transgenic breeding technology and gene editing to develop sustainable and high-yield crops. This sector addresses the growing need for sustainable agricultural solutions and improved crop resilience.
Minnesota's biotech sector is experiencing robust investment and funding trends. In the first half of 2025, biotech companies in the state raised at least $51.8 million, signaling strong investor confidence. The cumulative funding over recent years has propelled numerous startups and established companies alike, enabling significant advancements in research and product development.
The success of Minnesota's biotech industry is largely attributed to the support from leading research institutions such as the Mayo Clinic and the University of Minnesota. These institutions not only drive cutting-edge research but also facilitate technology transfer, enabling the creation of startups and fostering a collaborative environment. Additionally, organizations like the Minnesota Biotechnology Association provide essential networking, mentoring, and financing opportunities through regional accelerator programs and venture funds.
| Company Name | Location | Focus Area | Key Innovations |
|---|---|---|---|
| Cell Culture Company (C3) | Minneapolis | Therapeutics, Diagnostics | Comprehensive cell culture services across multiple industries |
| Francis Medical | Maple Grove | Cancer Treatment | Minimally invasive tissue ablation for prostate cancer |
| Geneticure | Minneapolis | Personalized Medicine | Precision medicine approaches for high blood pressure |
| Geneos Therapeutics | St. Paul | Immunotherapy | Personalized cancer immunotherapies |
| Invive | Minneapolis | Epigenetics | Health risk assessments based on epigenetic profiles |
| Celcuity | Minneapolis | Diagnostics | Advanced cancer and autoimmune disease diagnostics |
| Cerebral Therapeutics | St. Paul | Neurological Therapies | Innovative therapies for refractory neurological diseases |
| Cibus | St. Paul | Agricultural Biotechnology | Non-transgenic breeding and gene editing technologies |
The biotech sector in Minnesota is on a trajectory to raise over $1 billion in funding for the fourth time in five years. This surge reflects sustained investor interest and confidence in the region's ability to produce groundbreaking biotech innovations.
There is a growing focus on creating a more inclusive ecosystem within Minnesota's biotech industry. Efforts are being made to involve diverse perspectives and cater to underrepresented groups, fostering a more dynamic and innovative environment.
Companies are increasingly leveraging advanced technologies such as synthetic biology and gene editing to drive innovation. These technologies are integral to developing new agricultural solutions and advancing healthcare treatments, positioning Minnesota as a leader in these cutting-edge fields.
Minnesota's biotech industry is witnessing remarkable growth and innovation, supported by a robust ecosystem of leading research institutions, substantial funding, and a diverse range of companies specializing in various sectors. From personalized medicine and advanced diagnostics to agricultural biotechnology and immunotherapy, the state's biotech firms are making significant contributions to healthcare and beyond. With continued investment and a focus on inclusion and technological advancement, Minnesota is poised to remain a key player in the global biotech landscape.